Survival analysis in cancer refers to the proportion of patients who are alive from a point in time after diagnosis of cancer. It is expressed as the probability that a group of patients will "survive" for a given period, for example, 5 years, 10 years and 20 years.The results here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. R package 'survival' was utilized for survival analysis (Therneau T. 2023. A Package for Survival Analysis in R. R package version 3.5-5, https://CRAN.R-project.org/package=survival).

List of cancer types included in this analysis: Glioblastoma multiforme (GBM), Acute Myeloid Leukemia (LAML), Brain Lower Grade Glioma (LGG), Uveal Melanoma (UVM), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Breast invasive carcinoma (BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Ovarian serous cystadenocarcinoma (OV), Testicular Germ Cell Tumors (TGCT), Uterine Corpus Endometrial Carcinoma (UCEC), Uterine Carcinosarcoma (UCS), Cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Liver hepatocellular carcinoma (LIHC), Pancreatic adenocarcinoma (PAAD), Stomach adenocarcinoma (STAD), Adrenocortical carcinoma (ACC), Bladder Urothelial Carcinoma (BLCA), Kidney Chromophobe (KICH), Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), Pheochromocytoma and Paraganglioma (PCPG), Thyroid carcinoma (THCA), Thymoma (THYM), Head and Neck squamous cell carcinoma (HNSC), Mesothelioma (MESO), Sarcoma (SARC), Skin Cutaneous Melanoma (SKCM).